Natera GAAP EPS of -$0.42 misses by $0.15, revenue of $794M beats by $86.5M (NTRA:NASDAQ)
Natera (NTRA) reported Q3 GAAP EPS of -$0.42, missing estimates by $0.15. Revenue reached $794M, up 34.1% year-over-year, exceeding expectations by $86.5M. The company held $1.097B in cash and equivalents as of September 30, 2026, up from $1.076B at the end of 2025.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger a sell‑off, but the strong revenue growth could support a rebound if guidance improves.
Market read
First‑time Q3 earnings release with mixed results; likely short‑term price pressure for NTRA.
What to watch
Cash balance of $1.1B provides runway; upcoming product launches could offset the earnings miss.
Background
Natera is a NASDAQ‑listed genetic‑testing company that provides prenatal and oncology diagnostics.
Ticker impact
Natera reported Q3 GAAP EPS of -$0.42 (miss) and revenue of $794M (beat) in its first earnings release for the quarter.
likely downside as market prices in the EPS miss
EPS miss of $0.15 is material for a mid‑cap biotech; investors typically react negatively to profit shortfalls even with revenue growth.
Market effects
May weigh on other genetic‑testing and diagnostics firms as earnings expectations are reassessed.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking US biotech earnings.
Counterpoint
Revenue beat could signal longer‑term growth; investors might view the EPS miss as a short‑term accounting issue.
Key entities
- CompanyNatera
Genetic‑testing and diagnostics firm (NASDAQ: NTRA).
